Oral melatonin has no effect on appetite in advanced cancer

Oral melatonin has no effect on appetite in advanced cancer
Oral melatonin does not improve appetite, weight, or quality of life for patients with cachexia due to advanced cancer, according to research published online Feb. 25 in the Journal of Clinical Oncology.

(HealthDay)—Oral melatonin does not improve appetite, weight, or quality of life for patients with cachexia due to advanced cancer, according to research published online Feb. 25 in the Journal of Clinical Oncology.

In an effort to determine whether may be associated with appetite improvement in patients with cancer cachexia, Egidio Del Fabbro, M.D., of the University of Texas MD Anderson Cancer Center in Houston, and colleagues performed a randomized, double-blind, 28-day trial of melatonin 20 mg versus placebo in 48 patients with advanced lung or .

This study was closed for futility after the interim analysis was performed and results suggested that, even with a larger sample size, the results were not likely to change. No significant difference was observed between melatonin- and placebo-treated groups with regard to appetite, other symptoms, weight, score on the Functional Assessment of Anorexia/Cachexia Therapy questionnaire, toxicity, or survival.

"In cachectic patients with advanced lung or gastrointestinal cancer, oral melatonin 20 mg at night did not improve appetite, weight, or quality of life compared with placebo," the authors write. "More research is required to determine whether melatonin has a role in the supportive care of patients earlier in their disease ."

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

add to favorites email to friend print save as pdf

Related Stories

Heavy lifting for cancer research

Feb 09, 2012

Many patients with advanced cancer suffer from cachexia, a condition also called body-wasting or wasting syndrome, which causes significant weight loss, extreme fatigue and reduces quality of life.

Prophylaxis with apixaban feasible for cancer patients

Mar 29, 2012

(HealthDay) -- Primary venous thromboembolism prophylaxis with apixaban, an oral direct Factor Xa inhibitor, in ambulatory cancer patients undergoing first- or second-line chemotherapy for advanced or metastatic ...

Making headway on beta-blockers and sleep

Sep 28, 2012

Over 20 million people in the United States take beta-blockers, a medication commonly prescribed for cardiovascular issues, anxiety, hypertension and more. Many of these same people also have trouble sleeping, a side effect ...

L-carnitine does not reduce cancer-related fatigue

Sep 18, 2012

(HealthDay)—Patients with invasive malignancies who take L-carnitine supplements do not experience a reduction in fatigue, pain, or depression, according to research published online Sept. 17 in the Journal of ...

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

10 hours ago

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

14 hours ago

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.